Sharon, Elad

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 1,258

Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 919

Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy

Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 396

Current Landscape of Immunotherapy in Breast Cancer: A Review

Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 384

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program

Naqash, A. R., Moey, M. Y. Y., Cherie Tan, X.-W., Laharwal, M., Hill, V., Moka, N., Finnigan, S., Murray, J., Johnson, D. B., Moslehi, J. J., et al. (2022) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigation

Cited by 87